Nouvelles

Perceiv AI annonce aujourd’hui la clôture d’un financement de 1,5 M$. Perceiv AI est une société de médecine de précision qui prédit l’évolution des maladies neurodégénératives. Elle permet aux entreprises pharmaceutiques d’optimiser et de dé-risquer les essais cliniques, et aux médecins de poser un diagnostic plus précoce.

Cette étape de financement est composée d'investisseurs stratégiques et institutionnels du Canada et des États-Unis, dont CABHI (Centre for Aging + Brain Health Innovation), Plug and Play Ventures, Boreal Ventures, IKJ Capital, Red Abbey Labs, Investissement Québec, à titre de mandataire du gouvernement du Québec, et d'autres anges investisseur. « Nous sommes très heureux de pouvoir passer à l'étape suivante de notre croissance avec le soutien de ces investisseurs d'une importance stratégique », a affirmé le Dr Christian Dansereau, PDG de Perceiv AI.

Ces fonds serviront à l'expansion de la plateforme Foresight, la plateforme pronostique exclusive à Perceiv AI, qui est fondée sur des techniques d'intelligence artificielle et qui permet de prédire l'évolution de la maladie. L'entreprise cherche à s'adjoindre de ressources clés en recrutant de nouveaux talents pour faire avancer ses activités commerciales et scientifiques et renforcer ses efforts réglementaires.

Join Perceiv AI's senior scientist Angela Tam at our poster #LP005 "Mitigating loss of statistical power due to outcome imbalance in clinical trials" on Tuesday November 29 to Wednesday November 30 at Clinical Trials on Alzheimer's Disease (CTAD) 2022. Our team is excited to meet you in San Francisco, California next week.

Join Senior Scientist Dr. Angela Tam as she will give a talk on Perceiv AI’s latest work and performance gain for trial optimization and patients selection at the 2022 Alzheimer's Association International Conference (AAIC 2022) in the Novel Clinical Trial Designs and Outcome Measures session. Dr. Tam’s oral presentation will take place on August 2nd at 9:55am PT at the San Diego Convention Center. More info at: https://aaic.alz.org

Perceiv AI to present Foresight AD™, a novel prognostic tool to optimize Alzheimer's clinical trials, at the 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference.

We're happy to be virtually attending AAIC 2021 (Alzheimer’s Association International Conference). Dr. Angela Tam is presenting our poster #54702: A machine learning enrichment strategy for presymptomatic cohorts in Alzheimer's disease clinical trials.

Perceiv AI, announced it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data sciences.

More info about the NVIDIA Inception program here!

Perceiv AI announced a new international consortium project named Secure-e-Health initiative of €20M supported by the ITEA 3 program and will provide their expertise and AI-driven prognostic and predictive tools to this 8-country project’s 34 academic and private-sector partners. Drawing from several new technologies of partners, this ITEA3 project will create a fully integrated technology stack capable of supporting secure and privacy-preserving data analysis over fully separated datasets. The hope here is to remove some of the data silos that have prevented health innovation while preserving the privacy and security of that sensitive data between partners.

Ms. Madani Hermann is a strategy and innovation executive seasoned in general operations, commercialization, growth planning and execution across health and tech companies.

The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.

Perceiv AI announces support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) in the form of advisory services and research and development funding totaling $180,000 CAD to advance our Alzheimer's disease solution.

Perceiv AI is proud to announce today that it has been selected to join the 2020 San Francisco Canadian Technology Accelerator for Health cohort. “We are delighted to join the CTA San Francisco accelerator’s 2020 cohort. We greatly look forward to working with leading life science industry mentors to help further develop our innovative, lifesaving technologies targeting neurodegenerative and cardiovascular diseases,” said CEO and co-founder Christian Dansereau.

Perceiv AI presents a validation study of its prognostic enrichment tool for cognitive decline at the AAIC 2020 virtual conference - "Validation and Replication of a Prognostic Machine Learning Model for Enrichment of Cognitive Decliners in Clinical Trials".